MARKET

UPB

UPB

UpStream Bio Inc.
NASDAQ
8.51
-0.08
-0.87%
Opening 09:30 05/08 EDT
OPEN
8.64
PREV CLOSE
8.58
HIGH
8.64
LOW
8.51
VOLUME
6.89K
TURNOVER
--
52 WEEK HIGH
29.46
52 WEEK LOW
5.14
MARKET CAP
456.62M
P/E (TTM)
-6.3343
1D
5D
1M
3M
1Y
5Y
1D
Upstream Bio Advances Verekitug in Clinical Trials
TipRanks · 1d ago
Upstream Bio, Inc.: Strong Buy Rating Driven by Promising Drug Progress and Solid Financial Position
TipRanks · 1d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Talkspace (TALK) and Upstream Bio, Inc. (UPB)
TipRanks · 1d ago
Upstream Bio, Inc. reports Q1 results
Seeking Alpha · 1d ago
Upstream Bio Q1 EPS $(0.51) Misses $(0.49) Estimate, Sales $566.00K Beat $327.50K Estimate
Benzinga · 2d ago
UPSTREAM BIO: FIRST PATIENT IN PHASE 2 TRIAL OF VEREKITUG IN PATIENTS WITH COPD TO BE DOSED IN MID-2025
Reuters · 2d ago
Upstream Bio reports Q1 revenue $566k, consensus $326.25k
TipRanks · 2d ago
Weekly Report: what happened at UPB last week (0428-0502)?
Weekly Report · 3d ago
More
About UPB
More
Upstream Bio, Inc. is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist in clinical development, that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. It has advanced this highly potent monoclonal antibody into separate phase II trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and plans to initiate development in chronic obstructive pulmonary disease. TSLP is a member of a class of epithelial cytokines, also including IL-25 and IL-33, commonly referred to as alarmins. TSLP is primarily produced by epithelial cells, especially in the lung, gastrointestinal tract and skin.
Recently
Symbol
Price
%Change

Webull offers UpStream Bio Inc. stock information, including NASDAQ: UPB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, UPB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading UPB stock methods without spending real money on the virtual paper trading platform.